Biotech investor Arix Bioscience PLC (LON:ARIX) has confirmed that its investee company, Autolus Therapeutics PLC (NASDAQ:AUTL), has announced the launch of a proposed public offering in the United States.
The proposed maximum aggregate offering amount specified in the filing is 4mln American Depositary Shares (ADS), which does not include the underwriters’ option to purchase 600,000 additional ADS.
Each ADS represents one ordinary share. The final price per ADS in the offering will be determined following a book building process.
Arix shares were unchanged on Tuesday at 143p.